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Introduction
Osteoarthritis (OA) is one of the most common degenerative joint disease in the world, affecting more than 25% of the global population. 1 Chronic OA induces pain and joint dysfunction causing it to gradually become a serious socioeconomic burden. 2 It has been well documented that the primary characteristic of OA is the destruction of the structure and function of articular cartilage. 3 Although the underlying mechanism of OA remains poorly understood, inflammatory responses have been proposed to contribute significantly to the initiation and development of OA. 4 Furthermore, IL-1β has been described as a vital element responsible for the initiation and progression of OA via induction of proinflammatory and procatabolic responses. [4] [5] [6] [7] Chondrocytes account for the only cell type constituting articular cartilage, and hence, play an important role in maintaining the synthesis of normal tissues and renewal of aged extracellular matrix (ECM). 8, 9 The IL-1β-enhanced catabolic response serves to suppress the expression of cartilage-related genes and promote that of matrix-degrading related genes, including collagenases and matrix metalloproteinases (MMPs), which were previously reported to increase the anabolic activities of chondrocytes via promoting ECM degradation. 5, 10, 11 Moreover, IL-1β promotes chondrocytes to express inflammatory-related genes and proteins, such as INOS and COX-2, which reduce aggrecan and collagen II production, the primary components of cartilage ECM. [12] [13] [14] Thus, a candidate compound capable of targeting IL-1β-induced inflammation may prove effective as a novel OA therapeutic strategy.
Recent studies have highlighted the ability of naturally derived products to elicit anti-inflammatory effects without inducing significant adverse side effects. We have, therefore, chosen to also focus on a natural product, namely Morusin (Mor), a prenylated flavonoid isolated from the root bark of Morus australis (Moraceae). 15 This compound has been found to engage in a myriad of biological functions, including anti-inflammatory, antioxidative and antitumor activities. [16] [17] [18] For instance, Morusin was reported to attenuate LPS-induced proinflammatory responses in RAW264.7 cells. 19 Additionally, an in vivo study revealed that Morusin ameliorates 2, 4, 6-trinitrobenzene sulfonic acid sodium salt (TNBS)induced colitis in rats. 20 However, the precise effect and mechanism elicited by Morusin in OA remain unclear.
Herein, we examined the effects of Morusin in OA and its underlying mechanism in vitro and in vivo, in an attempt to determine whether Morusin has the potential to be a novel candidate for use in future OA treatment.
Materials and Methods Reagents
Morusin was obtained from MCE (New Jersey, USA), dissolved in dimethylsulfoxide (DMSO), and diluted in cell culture medium so that DMSO < 0.1% of the total volume. Recombinant human IL-1β, obtained from Peprotech (New Jersey, USA), was dissolved in water, and diluted in cell culture medium to a concentration of 10 ng/m for use in the study. Dulbecco's Modified Eagle Medium (DMEM/F12), fetal bovine serum (FBS), penicillin and streptomycin were purchased from Gibco (Rockville, MD, USA). Primary antibodies against actin, Type II Collagen and ADAMTS5 were purchased from Abcam (Cambridge, MA, USA), iNOS, COX-2, aggrecan, MMP-3, MMP-13, p65, P-p65, IκBα, P-erk, erk, P-JNK, JNK, P-p38, p38, PI3K, P-AKT, AKT were purchased from CST (Cambridge, MA, USA). RNAiso plus and SYBR Green Master Mix were purchased from Takara (Japan); and QuantiTect Reverse Transcription kit was purchased from Vazyme (Nanjing, China). All other reagents were purchased from Sigma-Aldrich (St Louis, MO, USA) unless otherwise stated.
Isolation and Culture of Chondrocytes
Ten 5-day-old C57BL/6 mice (five males and five females) were euthanized using an overdose of sodium pentobarbital, and cartilage was removed from the knee and hip joints. Cartilage was then minced and washed with phosphatebuffered saline (PBS), and centrifuged at 1000 rpm for 3 min. A total of 10 mL of 0.2% type II collagenase was added to the tissue and digestion was performed for 6-8 h in an incubator maintained at 5% CO2 and 37°C. Detached cells were collected, centrifuged at 1000 RPM for 3 min, transferred to a culture flask and incubated (37°C, 5% CO 2 ) for a further 24 h. Once 80% 0 -90% confluency was achieved, cells were harvested using 0.25% Trypsin-EDTA (Gibco, Invitrogen) and centrifuged at 1000 rpm for 5 min, after which the supernatant was discarded. The inner cell mass was collected and resuspended in DMEM/F12 supplemented with 10% FBS and 1% antibiotic mixture (penicillin and streptomycin). Finally, cells were plated at a density of 1 × 10 5 cells/mL in 6-well plates and incubated in a humidified atmosphere of 5% CO2 at 37°C. The media were changed every 2-3 days. Cells were passaged when 80% to 90% confluence was observed, using 0.25% trypsin-EDTA solution. Only passages 1 and 2 were used in our study to avoid phenotype loss.
Cytotoxicity Assays
Chondrocytes were seeded in 96-well plates at a density of 8000 cells/well. After culturing for 24 h, the medium was replaced with fresh culture medium containing various concentrations of Morusin (0, 1, 2, 4, 8, 16, 32 and 64 μM) for 24 and 48 h. Each Morusin concentration was repeated in 6 wells. At each time point, 10 μL CCK-8 reagent was added to each well, and cells were incubated for 4 h at 37°C. Next, the optical densities (ODs) were measured at 450 nm (Thermo Scientific, Multiskan GO, Waltham, MA, USA).
Western Blot Analysis
Total proteins were isolated from cultured chondrocytes using RIPA lysis buffer with 1 mM PMSF (Phenylmethanesulfonyl fluoride). The samples were incubated on ice for 30 min, and centrifuged for 10 min at 12,000 rpm and 4°C. The supernatant containing protein was collected, and the protein concentration was measured using a bicinchoninic acid (BCA) protein assay kit according to manufacturer's instructions. The protein was then mixed with sodium dodecyl sulfate-sampling buffer, followed by incubation at 95°C for 5 min. A total of 40 ng protein from each sample was loaded onto sodium dodecyl sulfate-polyacrylamide gels (SDS-PAGE) and separated by electrophoresis. Proteins were then transferred to PVDF membranes (Bio-Rad, USA), membranes were blocked with 5% nonfat milk for 2 h and incubated overnight with primary antibodies directed against collagen II (1:1000), iNOS (1:1000), COX-2 (1:1000), MMP-13 (1:1000), MMP-3 (1:1000), ADAMTS5 (1:1000), aggrecan (1:1000), p65 (1:1000), P-p65 (1:1000), IκBα (1:1000), P-erk (1:1000), erk (1:1000), P-JNK (1:1000), JNK (1:1000), P-p38 (1:1000), p38 (1:1000), PI3K (1:1000), P-AKT (1:1000), AKT (1:1000), actin (1:1000) at 4°C. Next, membranes were incubated with appropriate enzymelinked secondary antibodies for 2 h at room temperature. To visualize immunoblots, enhanced chemiluminescence (ECL) solution was added according to the manufacturer's instructions.
RNA Isolation and Quantitative Real-Time Polymerase Chain Reaction
Chondrocytes were seeded in DMEM/F-12 in 6-well plates at a density of 3 × 10 5 cells/mL and incubated for 24 h. Following stimulation with IL-1β and ALT at various concentrations (0, 0.5, 1, and 2 μM), total RNA was isolated from the monolayer of cultured chondrocytes using RNAiso plus (Takara, Japan). Total RNA (≤1000 ng) was reverse-transcribed into complementary DNA (cDNA) in a 20 μL-reaction volume using a Double-Strand cDNA Synthesis Kit (Takara, Japan). The PCR reaction was performed with 1 μL cDNA as template in triplicate using the Power SYBR ® Green PCR Master Mix (Takara, Japan) on the ABI StepOnePlus System (Applied Biosystems, Warrington, UK). The total volume (20 μL) for each PCR reaction consisted of 10 μL SYBR Green QPCR Master Mix, 8 μL ddH2O, 1 μL cDNA, and 10 μM each of forward and reverse primers. The cycling conditions were as follows: 95°C for 10 min (activation), followed by 40 cycles at 95°C for 10 s, 60°C for 20 s, and 72°C for 90 s. β-actin was utilized as the housekeeping gene, and independent experiments were repeated for a minimum of three times. The specific primers (based on mouse sequences) used are shown in Table 1 .
Immunofluorescence Microscopy
Chondrocytes were seeded on glass coverslips in a 12-well plate at a density of 2 × 10 5 cells/mL and treated under indicated conditions. At the end of each experiment, glass coverslips with chondrocyte monolayers were rinsed thrice in PBS. Cells were fixed with 4% paraformaldehyde for 30 min, and permeabilized in Triton X-100 for 10 min at room temperature. Following blocking with 5% BSA for 60 min, chondrocytes were incubated with primary antibodies against collagen II (1:500), MMP3 (1:500), MMP13 (1:500) and P65 (1:500) at 4°C overnight; after which they were incubated with Alexa Fluor 647conjugated anti-IgG secondary antibodies for 1 h and with DAPI for 5 min. Finally, images were observed using a Nikon ECLIPSE Ti microscope (Nikon, Japan).
Mice DMM Model
Thirty 10-week-old C57BL/6 female mice were purchased from the Animal Center of the Chinese Academy of Sciences (Shanghai, China). The protocol for animal care and use of laboratory animals was conducted in Table 1 Sequences of Primers Used in Real-Time Polymerase Chain Reaction (Real-Time PCR)
Gene
Forward Primer Reverse Primer , and were anesthetized, at which the mice knee joints were carefully, and aseptically, exposed with a scalpel, followed by resectioning of the medial meniscuses. The wound was later sutured carefully, and penicillin was injected intramuscularly for the following 3 days. The Mourusin-treated group was administered Morusin, dissolved in saline (40 mg/kg), intragastrically once every 2 days for 8 weeks; while mice in the Sham and DMM groups received 5% DMSO (dimethylsulfoxide) in saline once every 2 days for 8 weeks.
Histological Analysis
At the completion of the study, all knee joints were collected from mice, and fixed in 4% formaldehyde. Next, decalcifying solution was added for approximately 21 days to decalcify the calcium in knee joints. The knee joints were then embedded in paraffin, and sectioned coronally. Safranin O and hematoxylin and eosin (H & E) staining were performed to measure the extend of cartilage destruction.
Statistical Analysis
All experiments were performed a minimum of three times independently. Data are expressed as mean ± standard deviation (SD). Statistical analyses were conducted using Student's t-tests, one way ANOVA, or two-way ANOVA; p < 0.05 and p < 0.01 were considered statistically significant.
Results

Potential Cytotoxicity of Morusin on Chondrocytes
The chemical structure of Morusin is shown in Figure 1A , and the cell morphology of chondrocytes is provided in Figure 1B . Figure 1C ). Therefore, Morusin at concentration of 0, 0.5, 1 and 2 μM was used in subsequent experiments.
The Protective Effect of Morusin on IL-1β-Induced Inflammatory Reaction
As IL-1β was previously reported to contribute to the initiations and progression of OAvia induction of proinflammatory and procatabolic responses. We sought to further explore the protective effect of Morusin on IL-1β-induced chondrocytes inflammatory response. Results from qPCR analysis revealed treatment with IL-1β (10 ng/mL) dramatically increased the mRNA expression of inflammatory-related factors, such as TNF-α, IL-6, and INOS, while Morusin protected against these inflammatory responses (Figure 2A) . Similarly, Western blot analysis indicated that Morusin significantly attenuated the protein expression of inflammatory-related makers: INOS and COX-2, which were up-regulated following stimulation by IL-1β ( Figure 2B ).
Morusin Alleviates IL-1β-Induced ECM Degradation
Collagen II was previously reported as a primary component of ECM, where it contributes significantly to supporting the cartilaginous structure. 21 Thus, we next explored the effect of Morusin on collagen II. The results from Western blot ( Figure 3B ) and immunofluorescence ( Figure 4A and B, respectively) analysis indicated that Morusin protects against IL-1β-induced degradation of collagen II. The destruction of ECM structural integrity leads to OA pathology. Treatment with IL-1β induces this ECM degradation, thus promoting the process of OA. Similarly, MMPs are proteolytic enzymes that mediate ECM destruction during OA. [22] [23] [24] We, therefore, sought to explore the potential effect of Morusin on MMPs. qPCR results demonstrated that IL-1β up-regulated the expression of MMP-3, MMP-9 and MMP13, however, treatment with Morusin significantly attenuated this effect in a dose-dependent manner ( Figure 3A) . These results were confirmed via Western blot for MMP3 and MMP13 ( Figure 3C ).
Furthermore, immunofluorescence analysis also demonstrated that Morusin protected against IL-1β-induced expression of MMP3 and MMP13 ( Figure 4C and E cence assay is presented in Figure 4D and F. Aggrecan has been defined as a major component of ECM, endowing articular cartilage with the ability to withstand compressive loads. 25 Hence, the decrement of aggrecan has been shown to contribute to OA development. Our results demonstrate that IL-1β reduced aggrecan, while Morusin recovered its expression ( Figure 3C ). Furthermore, the ADAMTS family of metalloproteases cleaves aggrecan at a specific "aggrecanase" site. The absence of active ADAMTS5 was shown to prevent DovePress cartilage degradation in mouse OA. 26 Therefore, we investigated the effect of Morusin on IL-1β-induced expression of ADAMTS5, and found that Morusin significantly inhibited the expression of ADAMTS5 ( Figure 3C ).
Morusin Suppresses IL-1β-Induced Phosphorylation of the NF-κB Signaling Pathway
The NF-κB signaling pathway was previously reported to play a vital role in modulating matrix degradation, ECM synthesis as well as proinflammation. 27 We, therefore, further investigated the protective effect of Morusin on IL-1β activation of the NF-κB signaling pathway in chondrocytes. Results show that IL-1β significantly promoted the phosphorylation of p65, while Morusin dramatically attenuated phosphorylation in a time-dependent manner ( Figure 5A and B) . Moreover, IL-1β strongly increased the degradation of Iκβα; however, Morusin reversed this effect ( Figure 5A and B) . The immunofluorescence microscopy analysis also indicated that Morusin significantly decreased IL-1β-induced translocation of p65 from the cytoplasm to nucleus ( Figure 5C ). Statistical analysis for fluorescence data is presented in Figure 5D . Morusin did not impact IL-1β-Induced activation of MAPK and PI3K/AKT pathways.
MAPK and PI3K/AKT signaling pathways have also been shown to be vital for IL-1β-induced inflammation in OA pathology. [28] [29] [30] [31] Extracellular signal-regulated kinase p44/42 MAPK, c-Jun N-terminal kinase and p38 MAPK were demonstrated to be the main components of the MAPK signaling pathway. Further, a previous animal study reported that inhibition of p38 MAPK served to significantly protect against cartilage degradation. 32 JNK was also contributed to regulating the expression of MMP3; 23 while downregulating ERK decreased the expression of MMP13. 33 Otherwise, previous research revealed the critical role of the PI3K/ AKT pathway in regulating the production of MMPs by chondrocytes. 31 Cumulatively, these previous studies demonstrate the significant role of MAPKs and PI3K/AKT signaling pathways in L-1β-induced inflammation during OA pathology. We, therefore, sought to explore the effect of Morusin on these two pathways. Results revealed that Morusin treatment did not impact the phosphorylation of p38, ERK and JNK ( Figure 6A and B) . Moreover, the activation of AKT was not influenced by Morusin. Our data demonstrated that Morusin did not inhibit IL-1β-induced phosphorylation of MAPKs and PI3K/AKT signaling pathways ( Figure 6C and D) .
Morusin Decreases Cartilage Degeneration in a DMM OA Model
Since the in vitro data revealed a protective effect of Morusin on the inflammatory reaction associated with OA pathology, a surgically induced DMM model was established to verify whether Morusin protects against the development of OA in vivo. Ten-week-old mice were randomly divided into three groups (Sham group, DMM group, DMM+ Morusin treated group), and surgical DMM OA models were established, followed by intragastric administration of 40 mg/kg Morusin once every 2 days for 8 weeks in the treatment group; meanwhile, the Sham and DMM groups were intragastrically administrated 5% DMSO as a control. The intragastric administration continued until the end of study. Results from the Safranin O staining and H&E staining showed that compared with the Sham group, severe cartilage erosion and cartilage destruction were observed in DMM group ( Figure 7A) ; however, treatment with Morusin reversed the destruction. Further, the OARSI scores were much higher in the OA compared to the Sham group. Similarly, treatment with Morusin reduced the OARSI scores ( Figure 7B ). Cumulatively, these results demonstrate that Morusin may serve as a potential candidate for the treatment of OA.
Discussion
Osteoarthritis (OA) is a chronic bone disease characterized by degeneration of articular cartilage. 34 In late stages of osteoarthritis, intensive cartilage ECM degradation leads to development of fissures, fibrillation and narrow joint spaces, aggrandizing joint friction, structural remodeling and functional impairment. Current therapeutic strategies including physical therapy and pain-relieving drugs only relieve the symptoms and often elicit adverse side effects. 35 Therefore, a valid agent is urgently required to attenuate the initiation and development of OA. Previous studies had revealed the important therapeutic potential of Morusin, a Chinese herbal medicine, in inflammatory processes. In fact, Morusin was believed to reduce the inflammatory reaction in several diseases. 17, 36, 37 We, therefore, explored whether it possessed anti-inflammatory properties in osteoarthritis. Our data demonstrate that Morusin significantly inhibits the IL-1β-induced inflammatory reaction in chondrocytes; potentially via suppression of the NF-κB signaling pathway. Previously, inflammation has been shown to contribute significantly to the initiation and development of OA. 38 During the pathological process of OA, inflammatory mediators, most notably IL-1β, induce the release of other proinflammatory cytokines, thereby promoting the chondrocytes catabolic response and destroying the structure of articular cartilage. 39 Candidate molecules capable of targeting IL-1-induced inflammation were, therefore, postulated to be potential novel therapeutic strategies for OA. IL-1β promotes the expression of INOS and COX-2. 40 INOS synthesizes the inflammatory mediator NO, 41, 42 and COX-2 is a major mediator of inflammation and pain in the pathological process of OA. 43 Hence, specific inhibitors of COX-2 are now used clinically to treat OA. 44 Our data demonstrate that Morusin significantly inhibited IL-1βinduced expression of INOS and COX-2, further supporting its anti-inflammatory properties in vitro.
Since the articular cartilage of ECM maintains mechanical load distribution generated by weight, its degradation directly leads to joint morbidity. 45 Complex enzyme systems lead to the breakdown of ECM, 46 with metalloproteinases (MMPs) reported to be responsible for the cataplasia involved in ECM degradation. 47 secretion of MMP3 and MMP13, 48, 49 disrupts the synthesis/ degradation equilibrium of ECM. 50 In fact, accumulating evidence has shown that MMP3 and MMP13 downregulation may function as a therapeutic target for OA. 51, 52 In addition, type II collagen and aggrecan comprise the primary components of ECM, meeting the demands of weightbearing mechanical stress. 21, 53 IL-1β inhibits the expression of type II collagen and aggrecan, 54, 55 thus disrupting the stability of articular cartilage and promoting the initiation of OA. Our data indicate that Morusin significantly suppresses the expression of MMP3 and MMP13, while rescuing the degeneration of type II collagen and aggrecan, thus protecting against ECM degradation, and delaying the process of OA. Furthermore, convincing evidence has demonstrated the vital role of ADAMTS-5 in modulating degradation of aggrecan. Stimulation with IL-1β upregulated ADAMTS-5 expression, which then functions to cleave aggrecan. 55, 56 We thus explored the effect of Morusin on ADAMTS-5 and found that Morusin protects against IL-1β-induced stimulation of ADAMTS-5. 
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Activation of the NF-κB signaling pathway is reported to stimulate the expression of inflammatory cytokines and ECM degradation products, leading to initiation of OA. 57 Under normal conditions, NF-κB is localized in the cytoplasm where it binds IκBα. Once chondrocytes become simulated by IL-1β, NF-κB is freed from the cytoplasm and translocated to the nucleus, 27 where it triggers the expression of inflammatory-related genes, including COX-2, INOS, and IL-6. 57 Agents that target NF-κB signaling may protect against IL-1β induced chondrocyte inflammatory reactions. 58, 59 We, therefore, determined the effect of Morusin on IL-1β-induced p65 phosphorylation and IκBα degradation. Results show that Morusin significantly inhibited the activation of p65 and induced the degradation of IκBα in chondrocytes in a time-dependent manner.
Following confirmation of the protective effect of Morusin in vitro, we performed surgical DMM in a mouse model to further explore whether Morusin could protect against OA in vivo. This DMM model was previously shown to serve as a mature model that mimics OA pathology. 60 OARSI scoring was also performed to evaluate the degree of cartilage degeneration. Results revealed that Morusin ameliorated cartilage erosion in vivo. These data along, with that from the in vitro study, suggest Morusin as a potential therapy drug for future OA treatment.
Conclusion
In conclusion, our study indicates that Morusin may serve as a potential agent in treating IL-1β-induced chondrocyte inflammatory reaction in vitro as well as DMM-induced cartilage degeneration in vivo. The suppression of Il-1β-induced activation of NF-κB and degradation of IκB α is considered to be the primary mechanism of action for Morusin. However, their certain limitations were noted in this study. First, the effect of Morusin on other important factors such as IKKα and P-IκBα in the NF-κB signaling pathway was not examined and thus, remain unclear. Second, the immunohistochemical staining of IL-1β in articular cartilage was not performed. We would like to explore these areas in our future studies.
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